In a new randomized controlled trial, older individuals taking daily low-dose aspirin faced a 20% higher risk of developing anemia, even without prior major bleeding events. The study analyzed data from the Aspirin in Reducing Events in the Elderly (ASPREE) trial, focusing on hemoglobin concentrations in healthy older patients. Anemia, a common condition among the elderly, can lead to various symptoms and worsen existing health issues. Changes in aspirin recommendations for cardiovascular disease prevention highlight the importance of individualized decisions regarding aspirin use. Long-term aspirin use may persist among older adults despite updated guidelines. The study revealed a 20% increased risk of anemia with aspirin therapy and lower ferritin levels in aspirin users compared to the placebo group. Clinicians are advised to monitor hemoglobin levels closely in older patients taking aspirin and consider alternative treatment options.
Till ett annat språk
från källinnehåll
www.medscape.com
Viktiga insikter från
by Kelly Ragan på www.medscape.com 06-20-2023
https://www.medscape.com/viewarticle/993420Djupare frågor